Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • IDF

    - PMLiVE

    Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

    Approximately 38.4 million people in the US are affected by diabetes

    - PMLiVE

    Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

    The company is planning to submit regulatory applications for the candidate by the end of the year

    regeneron headquarters

    Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn

    The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study

    - PMLiVE

    Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

    UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

    - PMLiVE

    Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

    The company is expecting to file for the first regulatory approval of the drug next year

    - PMLiVE

    Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

    The progressive condition affects approximately 40% of type 2 diabetes patients

    - PMLiVE

    Novo shares promising results for high-dose semaglutide in late-stage obesity study

    The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

    - PMLiVE

    Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases

    The partners are aiming to develop new drugs for type 2 diabetes, obesity and cardiovascular disease

    - PMLiVE

    Eli Lilly announces $3bn expansion to US injectables manufacturing facility

    The investment will help Lilly meeting the growing demand for its diabetes and obesity medicines

    - PMLiVE

    Sanofi unveils plans to build €1bn insulin production base in China

    The site will focus on serving the insulin medication needs of local diabetic patients

    - PMLiVE

    Amgen’s investigational weight-loss drug MariTide shows promise in mid-stage study

    The company has announced a phase 3 programme across obesity and related conditions

    - PMLiVE

    Common antidiabetic drug metformin found to slow growth of precancerous cells

    The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links